A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase III Study of Regorafenib in Patients W/ Hepatocellular Grant uri icon

date/time interval

  • February 21, 2013 - February 20, 2016

total award amount

  • 106429.43

direct costs

  • 85143.54

sponsor award ID

  • 0BAY 73-4506/15982

local award ID

  • 00088152